Roche ’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints

Basel, 19 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) and whose tumours had PTEN loss. In this patient group, ipatasertib in combination with abiraterone and prednisone/prednisolone provided a statistically significant reduction in the risk of disease worsening or death, compared to current standard of care (abiraterone and prednisone/prednisolone) plus placebo. The other co-primary endpoint of rPFS in the overall study population (ITT) was not met. The safety profile for the combination of ipatasertib and abiraterone was consistent with previous analyses and known risks. The results of the IPATential150 study will be presented at an upcoming medical meeting.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news

Related Links:

Conclusion: Our results confirm the value of plasma testing for HRRm status when there is insufficient high-quality tissue for multi-gene molecular testing. We show that patients with mCRPC benefit from the combination of olaparib and abiraterone treatment regardless of HRRm status. The combination is currently being further investigated in the Phase III PROpel trial.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
CONCLUSION: Retrospective real-world data show a significantly longer RPFS for mHSPC patients treated with ADT + AAP compared to ADT only or ADT + docetaxel at short-term follow-up. This can aid in counselling of mHSPC patients in daily clinical practice.PMID:34789066 | DOI:10.1080/17843286.2021.2001999
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: PARP inhibitor efficacy is diminished in BRCA1- versus BRCA2-altered mCRPC. This is not due to an imbalance in germline mutations but might be related to more monoallelic mutations and/or concurrent TP53 alterations in the BRCA1 group.PMID:34778690 | PMC:PMC8575434 | DOI:10.1200/PO.21.00070
Source: Ann Oncol - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: We have demonstrated the feasibility to track prostate motion based on real-time orthogonal cine MRI without implanting fiducials. With further investigation on more patients and following careful workflow, the real-time motion tracking technique may be implemented in MRgART to manage intrafraction motion.AUTHOR DISCLOSURE: H. Jassar: None. A. Tai: None. X. Chen: None. T. Keiper: None. E.S. Paulson: Research Grant; Siemens Healthineers, Elekta Instruments AB.F. Lathuiliere: None. S. Bériault: None. D. Cooper: None. F. Hebert: None. L. Savard: None. S. Cloake: None. W.A. Hall: Research Grant; Elekta, Nati...
Source: Physics in Medicine and Biology - Category: Physics Authors: Source Type: research
CONCLUSION: The fiducial-based real-time prostate motion tracking during tomotherapy is advantageous, even in the presence of the measurable IFMs. Our results indicate that, to reduce/eliminate the effect of the fiducial migration on motion tracking stability and accuracy, the fiducial positions on the daily MVCT, instead of the planning CT in the current setting, should be used as the baseline.AUTHOR DISCLOSURE: G. Chen: North Central Chapter of AAPM, Medical College of Wisconsin. A. Tai: None. E.A. Omari: None. M. Bedi: None. C.A. Lawton: None. A. Li: Research Grant; Elekta AB, Accuray Inc, Siemens Healthineers, Manteia ...
Source: Physics in Medicine and Biology - Category: Physics Authors: Source Type: research
CONCLUSION: We have demonstrated the feasibility to track prostate motion based on real-time orthogonal cine MRI without implanting fiducials. With further investigation on more patients and following careful workflow, the real-time motion tracking technique may be implemented in MRgART to manage intrafraction motion.AUTHOR DISCLOSURE: H. Jassar: None. A. Tai: None. X. Chen: None. T. Keiper: None. E.S. Paulson: Research Grant; Siemens Healthineers, Elekta Instruments AB.F. Lathuiliere: None. S. Bériault: None. D. Cooper: None. F. Hebert: None. L. Savard: None. S. Cloake: None. W.A. Hall: Research Grant; Elekta, Nati...
Source: Physics in Medicine and Biology - Category: Physics Authors: Source Type: research
CONCLUSION: The fiducial-based real-time prostate motion tracking during tomotherapy is advantageous, even in the presence of the measurable IFMs. Our results indicate that, to reduce/eliminate the effect of the fiducial migration on motion tracking stability and accuracy, the fiducial positions on the daily MVCT, instead of the planning CT in the current setting, should be used as the baseline.AUTHOR DISCLOSURE: G. Chen: North Central Chapter of AAPM, Medical College of Wisconsin. A. Tai: None. E.A. Omari: None. M. Bedi: None. C.A. Lawton: None. A. Li: Research Grant; Elekta AB, Accuray Inc, Siemens Healthineers, Manteia ...
Source: Physics in Medicine and Biology - Category: Physics Authors: Source Type: research
Arch Pathol Lab Med. 2021 Oct 20. doi: 10.5858/arpa.2021-0104-OA. Online ahead of print.ABSTRACTCONTEXT.—: Effect of tumor nodule (TN) location in the prostate on adverse radical prostatectomy (RP) outcomes is not well studied in contemporary cohort.OBJECTIVE.—: To investigate the significance of TN location with respect to extraprostatic extension (EPE), seminal vesicle invasion (SV+), and positive margin status (SM+) in 1388 RPs.DESIGN.—: Each TN at RP was independently graded, staged, and volumetrically assessed. TNs with at least 80% of their volume occupying either the anterior or posterior part of t...
Source: Archives of Pathology and Laboratory Medicine - Category: Laboratory Medicine Authors: Source Type: research
This study is a significant contribution to implementation science, providing VHA an opportunity to ensure delivery of high-quality care at the lowest cost using a theory-based approach. The study is ongoing. Preliminary data collection and recruitment have started; analysis has yet to be performed.Trial registrationCliniclTrials.gov NCT03445559. Prospectively registered on February 26, 2018
Source: Trials - Category: Research Source Type: clinical trials
For prostate cancer, use of elective pelvic lymph node radiotherapy (PNRT) is controversial, and investigators have been aiming to find a role for the treatment for over 50 years. The fundamental premise for recommending PNRT is that a subset of patients with radiographic node negative disease will harbor pathologically node positive disease, and PNRT would translate into improved oncologic outcomes with minimal additional toxicity.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Pharmaceuticals | Prednisolone | Prednisone | Prostate Cancer | Radiography | Statistics | Study